Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.04% Market Closed
Market Cap: 3.6B USD
Have any thoughts about
Axonics Inc?
Write Note

Axonics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Axonics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Axonics Inc
NASDAQ:AXNX
Operating Income
-$7.2m
CAGR 3-Years
51%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Operating Income
$2.9B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
6%
Boston Scientific Corp
NYSE:BSX
Operating Income
$2.9B
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
11%
Stryker Corp
NYSE:SYK
Operating Income
$4.8B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Operating Income
$6.9B
CAGR 3-Years
-7%
CAGR 5-Years
10%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Operating Income
$2.1B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
14%
No Stocks Found

Axonics Inc
Glance View

Market Cap
3.6B USD
Industry
Health Care

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 517 full-time employees. The company went IPO on 2018-10-31. The company is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). The company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. The company offers urethral bulking agent, Bulkamid for stress urinary incontinence.

AXNX Intrinsic Value
33.81 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Axonics Inc's Operating Income?
Operating Income
-7.2m USD

Based on the financial report for Sep 30, 2024, Axonics Inc's Operating Income amounts to -7.2m USD.

What is Axonics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
36%

Over the last year, the Operating Income growth was 33%. The average annual Operating Income growth rates for Axonics Inc have been 51% over the past three years , 36% over the past five years .

Back to Top